AstraZeneca’s (AZN) Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. The approval was granted by the Food and Drug Administration, FDA, after securing Priority Review and Breakthrough Therapy Designation. It was based on results from the ADRIATIC Phase III trial which were presented during the Plenary Session of the 2024 American Society of Clinical Oncology, ASCO, Annual Meeting and subsequently published in the New England Journal of Medicine. In the trial, Imfinzi reduced the risk of death by 27% versus placebo and also reduced the risk of disease progression or death by 24%.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca appoints Iskra Reic as Executive Vice President, International
- AstraZeneca (AZN) Sees Its Cancer Drug Added to China’s Reimbursement List
- AstraZeneca announces results from CAPItello-281 trial
- AstraZeneca’s Truqap combo demonstrated statistically significant improvement
- IonQ (IONQ) Stock Lacks Needed Catalysts
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
